Day One Biopharmaceuticals (DAWN) News Today $12.54 +0.14 (+1.13%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from AnalystsShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given an average recommendation of "Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have issued a bJanuary 17 at 2:33 AM | marketbeat.comStrategic Positioning and Growth Potential of Day One Biopharmaceuticals: A Buy Rating Driven by Ojemda’s Market PenetrationJanuary 16 at 4:44 PM | markets.businessinsider.comNeedham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)January 15 at 3:29 AM | americanbankingnews.comBank of America Securities Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)January 15 at 3:19 AM | markets.businessinsider.comOptimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy RatingJanuary 13, 2025 | markets.businessinsider.comDay One Biopharmaceuticals preliminary FY24 OJEMDA product revenue $57.2MJanuary 13, 2025 | markets.businessinsider.comDay One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate PrioritiesJanuary 13, 2025 | finance.yahoo.comDay One Biopharmaceuticals' (DAWN) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday.January 13, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month Low - What's Next?Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - Here's WhyJanuary 10, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Price Target Cut to $25.00 by Analysts at Bank of AmericaBank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday.January 7, 2025 | marketbeat.comTop 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)January 7, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short InterestDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 18,100,000 shares, a decline of 7.1% from the November 30th total of 19,490,000 shares. Currently, 24.9% of the shares of the company are sold short. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is presently 16.6 days.December 30, 2024 | marketbeat.comGeode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Geode Capital Management LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 10.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,432,697 shares of the company's stock after buying an addDecember 29, 2024 | marketbeat.comDay One Biopharmaceuticals: Sales Figures In The CrosshairsDecember 25, 2024 | seekingalpha.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned an average rating of "Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have given a buy recommDecember 23, 2024 | marketbeat.comDay One to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | globenewswire.comFranklin Resources Inc. Has $55.34 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Franklin Resources Inc. lifted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 2.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,869,632 shares of the company's stock after pDecember 17, 2024 | marketbeat.comDay One price target lowered to $34 from $39 at JonesResearchDecember 17, 2024 | markets.businessinsider.comWellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Wellington Management Group LLP lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 142.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 721,581 shares of the company's stock aDecember 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Charles Schwab Investment Management Inc. increased its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 14.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 507,448 shares ofDecember 12, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Frazier Life Sciences Management L.P. purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 689,655 shares of the company'December 10, 2024 | marketbeat.comJanus Henderson Group PLC Grows Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Janus Henderson Group PLC lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 18.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,177,197 shares of the company's stock after acquiring anDecember 7, 2024 | marketbeat.comDay One Biopharmaceuticals (DAWN) Gets a Buy from Piper SandlerDecember 6, 2024 | markets.businessinsider.comSamsara BioCapital LLC Lowers Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Samsara BioCapital LLC lowered its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 25.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 147,319 shares of the company's stock after selling 49,106 shares during the period.December 5, 2024 | marketbeat.comFmr LLC Has $103.25 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Fmr LLC lifted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 178.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,412,380 shares of the company's stock after acquiring an additional 4,75December 5, 2024 | marketbeat.comErste Asset Management GmbH Purchases New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Erste Asset Management GmbH acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 51,200 shares of the company's stock, valued at approximately $725,000. ErsteDecember 4, 2024 | marketbeat.comAlgert Global LLC Purchases 50,990 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Algert Global LLC boosted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 248.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 71,487 shares of the company's stock after purchasing an addNovember 30, 2024 | marketbeat.comBraidwell LP Purchases 1,837,949 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Braidwell LP grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 60.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,873,853 shares of the company's stock after acquiringNovember 29, 2024 | marketbeat.comVestal Point Capital LP Buys 1,250,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Vestal Point Capital LP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 100.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,500,000 shareNovember 29, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by AnalystsShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have been given a consensus recommendation of "Buy" by the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have asNovember 28, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has received a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recNovember 28, 2024 | marketbeat.comWhy Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?November 27, 2024 | msn.comDay One Biopharmaceuticals announces R&D leadership changeNovember 22, 2024 | uk.investing.comDay One Biopharmaceuticals announces executive retirementNovember 22, 2024 | uk.investing.comDay One Biopharmaceuticals Announces Leadership TransitionNovember 21, 2024 | markets.businessinsider.comDay One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & DevelopmentNovember 20, 2024 | globenewswire.comFirst Turn Management LLC Makes New Investment in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)First Turn Management LLC purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 947,878 shares of theNovember 19, 2024 | marketbeat.comShort Interest in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Rises By 12.8%Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 18,020,000 shares, a growth of 12.8% from the October 15th total of 15,980,000 shares. Based on an average trading volume of 1,020,000 shares, the days-to-cover ratio is currently 17.7 days. Currently, 26.4% of the shares of the company are short sold.November 18, 2024 | marketbeat.comDay One to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 18, 2024 | globenewswire.com59,259 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Bought by GSA Capital Partners LLPGSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 59,259 shares of the company's stock, valued at approximNovember 17, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 10,000 SharesNovember 13, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 8.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,827,695 shares of the company's sNovember 11, 2024 | marketbeat.comSamuel C. Blackman Sells 11,245 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) StockNovember 9, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $180,257.35 in StockDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 11,245 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $16.03, for a total value of $180,257.35. Following the completion of the sale, the insider now directly owns 1,085,790 shares in the company, valued at $17,405,213.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.November 8, 2024 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Upgraded by TD CowenTD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday.November 5, 2024 | marketbeat.comBullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ForecastsNovember 4, 2024 | finance.yahoo.comDay One Biopharmaceuticals: Strong Ojemda Launch Exceeds Expectations, Analyst Reiterates Overweight RatingNovember 4, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for DAWN Q1 Earnings?Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Thursday, October 31st. HC Wainwright analyst A. Maldonado forecasts that the comNovember 4, 2024 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have asNovember 3, 2024 | marketbeat.comWe Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business GrowthNovember 2, 2024 | finance.yahoo.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼0.490.68▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼94▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viking Therapeutics News Today Axsome Therapeutics News Today Krystal Biotech News Today TG Therapeutics News Today Organon & Co. News Today Scholar Rock News Today Alvotech News Today Ultragenyx Pharmaceutical News Today ADMA Biologics News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
